RSS

Trelegy Ellipta

GlaxoSmithKline (GSK) has announced that its once-daily single inhaler triple therapy, Trelegy Ellipta, for the treatment of chronic obstructive pulmonary disease (COPD) has been granted marketing authorisation by the European Commission. more

Technology